New York State Common Retirement Fund Buys 25,902 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

New York State Common Retirement Fund lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 47.0% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 80,986 shares of the company's stock after acquiring an additional 25,902 shares during the quarter. New York State Common Retirement Fund owned approximately 0.10% of IDEXX Laboratories worth $34,010,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in IDXX. MorganRosel Wealth Management LLC acquired a new position in IDEXX Laboratories in the first quarter valued at about $26,000. Hurley Capital LLC bought a new position in shares of IDEXX Laboratories during the fourth quarter worth approximately $29,000. Colonial Trust Co SC increased its stake in IDEXX Laboratories by 84.8% during the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company's stock worth $35,000 after acquiring an additional 39 shares during the period. Itau Unibanco Holding S.A. increased its stake in shares of IDEXX Laboratories by 540.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock valued at $40,000 after purchasing an additional 81 shares during the last quarter. Finally, Retirement Wealth Solutions LLC increased its stake in shares of IDEXX Laboratories by 40.0% in the 1st quarter. Retirement Wealth Solutions LLC now owns 105 shares of the company's stock valued at $44,000 after purchasing an additional 30 shares during the last quarter. Institutional investors own 87.84% of the company's stock.

Analysts Set New Price Targets

IDXX has been the topic of several recent research reports. Wall Street Zen raised IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Saturday. Morgan Stanley boosted their price objective on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a research note on Monday, May 5th. Leerink Partners boosted their target price on IDEXX Laboratories from $515.00 to $580.00 and gave the company an "outperform" rating in a research report on Wednesday, June 11th. Jefferies Financial Group started coverage on IDEXX Laboratories in a research report on Tuesday, July 1st. They issued a "buy" rating and a $625.00 target price for the company. Finally, Stifel Nicolaus boosted their price objective on IDEXX Laboratories from $510.00 to $540.00 and gave the stock a "hold" rating in a report on Wednesday, July 2nd. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, IDEXX Laboratories presently has a consensus rating of "Moderate Buy" and a consensus price target of $558.11.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock traded down $6.09 during trading on Wednesday, hitting $520.57. The stock had a trading volume of 471,824 shares, compared to its average volume of 645,843. The stock has a market cap of $41.86 billion, a price-to-earnings ratio of 48.11, a price-to-earnings-growth ratio of 3.84 and a beta of 1.54. The stock's 50 day moving average is $522.55 and its two-hundred day moving average is $461.26. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $549.52. The company has a quick ratio of 0.81, a current ratio of 1.16 and a debt-to-equity ratio of 0.31.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.93 by $0.03. The firm had revenue of $998.43 million for the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The business's quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.71 earnings per share. As a group, analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director M Anne Szostak sold 1,260 shares of the stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total value of $645,548.40. Following the transaction, the director owned 1,801 shares of the company's stock, valued at $922,724.34. This represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.98% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.